didn't anyone here actually read the study?... or are you just blindly believing whatever microsoft news puts in your feed bag?

msn.com/en-us/health/mindandbody/tumors-just-vanished-cancer-patients-now-in-remission-after-drug-trial/vi-AAY9tLH

A paper published on Sunday at The New England Journal of Medicine outlined a study of 18 rectal cancer patients who were given dostarlimab every three weeks for six months and ended up cancer-free, including the first patient who is now two years out from the trial.

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer..

https://en.wikipedia.org/wiki/Dostarlimab#Side_effects

Serious adverse reactions in >2% of patients included sepsis, acute kidney injury, urinary tract infection, abdominal pain, and pyrexia.[4][5]
Immune-mediated adverse reactions can occur including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis.[4][5]

>2%

> = Greater than
< = Less than

Greater than 2%?

ok...

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf

Serious adverse reactions occurred in 34% of patients receiving JEMPERLI. Serious adverse reactions in >2% of patients included sepsis (2.9%), acute kidney injury (2.9%), urinary tract infection (2.9%), abdominal pain (2.9%), and pyrexia (2.9%). JEMPERLI was permanently discontinued due to adverse reactions in 5 (4.8%) patients, including transaminases increased, sepsis, bronchitis, and pneumonitis. Dosage interruptions due to an adverse reaction occurred in 23% of patients who received JEMPERLI. Adverse reactions that required dosage interruption in ≥1% of patients who received JEMPERLI were anemia, diarrhea, increased lipase, and pyrexia. The most common adverse reactions (≥20%) were fatigue/asthenia, nausea, diarrhea, anemia, and constipation. The most common Grade 3 or 4 adverse reactions (≥2%) were anemia and transaminases increased.

Fake news.